These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9527763)

  • 1. Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients.
    De Wit S; Debier M; De Smet M; McCrea J; Stone J; Carides A; Matthews C; Deutsch P; Clumeck N
    Antimicrob Agents Chemother; 1998 Feb; 42(2):223-7. PubMed ID: 9527763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteers.
    Purkins L; Wood N; Kleinermans D; Love ER
    Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):62-8. PubMed ID: 14616416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virus.
    Ofotokun I; Acosta EP; Lennox JL; Pan Y; Easley KA
    Pharmacotherapy; 2008 Jan; 28(1):74-81. PubMed ID: 18154477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1.
    Murphy RL; Sommadossi JP; Lamson M; Hall DB; Myers M; Dusek A
    J Infect Dis; 1999 May; 179(5):1116-23. PubMed ID: 10191212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trimethoprim/sulfamethoxazole does not affect the steady-state disposition of indinavir.
    Sturgill MG; Seibold JR; Boruchoff SE; Yeh KC; Haddix H; Deutsch P
    J Clin Pharmacol; 1999 Oct; 39(10):1077-84. PubMed ID: 10516943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
    Riddler SA; Havlir D; Squires KE; Kerr B; Lewis RH; Yeh K; Wynne LH; Zhong L; Peng Y; Deutsch P; Saah A
    Antimicrob Agents Chemother; 2002 Dec; 46(12):3877-82. PubMed ID: 12435691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.
    Gatti G; Vigano' A; Sala N; Vella S; Bassetti M; Bassetti D; Principi N
    Antimicrob Agents Chemother; 2000 Mar; 44(3):752-5. PubMed ID: 10681350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.
    Merry C; Barry MG; Ryan M; Tjia JF; Hennessy M; Eagling VA; Mulcahy F; Back DJ
    AIDS; 1999 Oct; 13(15):F101-7. PubMed ID: 10546851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.
    Levin GM; Nelson LA; DeVane CL; Preston SL; Eisele G; Carson SW
    Psychopharmacol Bull; 2001; 35(2):62-71. PubMed ID: 12397887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin.
    Boruchoff SE; Sturgill MG; Grasing KW; Seibold JR; McCrea J; Winchell GA; Kusma SE; Deutsch PJ
    Clin Pharmacol Ther; 2000 Apr; 67(4):351-9. PubMed ID: 10801243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fluconazole on the steady-state pharmacokinetics of delavirdine in human immunodeficiency virus-positive patients.
    Borin MT; Cox SR; Herman BD; Carel BJ; Anderson RD; Freimuth WW
    Antimicrob Agents Chemother; 1997 Sep; 41(9):1892-7. PubMed ID: 9303380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin.
    Hamzeh FM; Benson C; Gerber J; Currier J; McCrea J; Deutsch P; Ruan P; Wu H; Lee J; Flexner C;
    Clin Pharmacol Ther; 2003 Mar; 73(3):159-69. PubMed ID: 12621381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir.
    Cato A; Cao G; Hsu A; Cavanaugh J; Leonard J; Granneman R
    Drug Metab Dispos; 1997 Sep; 25(9):1104-6. PubMed ID: 9311629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered pharmacokinetics of indinavir by a novel nonnucleoside reverse transcriptase inhibitor (HBY-097): a pharmacokinetic evaluation in HIV-positive patients.
    Hayashi S; Jayesekera D; Jayewardene A; Shah A; Thevanayagam L; Aweeka F
    J Clin Pharmacol; 1999 Oct; 39(10):1085-93. PubMed ID: 10516944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir.
    Tappouni HL; Rublein JC; Donovan BJ; Hollowell SB; Tien HC; Min SS; Theodore D; Rezk NL; Smith PC; Tallman MN; Raasch RH; Kashuba AD
    Am J Health Syst Pharm; 2008 Mar; 65(5):422-8. PubMed ID: 18281734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of indinavir with or without low-dose ritonavir in HIV-infected Thai patients.
    Burger D; Boyd M; Duncombe C; Felderhof M; Mahanontharit A; Ruxrungtham K; Ubolyam S; Stek M; Cooper D; Lange J; Phanupak P; Reiss P
    J Antimicrob Chemother; 2003 May; 51(5):1231-8. PubMed ID: 12668574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.
    Aarnoutse RE; Wasmuth JC; Fätkenheuer G; Schneider K; Schmitz K; de Boo TM; Reiss P; Hekster YA; Burger DM; Rockstroh JK
    Antivir Ther; 2003 Aug; 8(4):309-14. PubMed ID: 14518700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers.
    Slain D; Amsden JR; Khakoo RA; Fisher MA; Lalka D; Hobbs GR
    Pharmacotherapy; 2005 Feb; 25(2):165-70. PubMed ID: 15767232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of indinavir and ritonavir administered at 667 and 100 milligrams, respectively, every 12 hours compared with indinavir administered at 800 milligrams every 8 hours in human immunodeficiency virus-infected patients.
    Rhame FS; Rawlins SL; Petruschke RA; Erb TA; Winchell GA; Wilson HM; Edelman JM; Abramson MA
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4200-8. PubMed ID: 15504842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of effect of simultaneously administered didanosine encapsulated enteric bead formulation (Videx EC) on oral absorption of indinavir, ketoconazole, or ciprofloxacin.
    Damle BD; Mummaneni V; Kaul S; Knupp C
    Antimicrob Agents Chemother; 2002 Feb; 46(2):385-91. PubMed ID: 11796346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.